drugset / Trial / NCT03590210
Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
Phase 2
Completed
92 enrolled
University Medicine Greifswald
Bristol-Myers Squibb · collabInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · collabPharmaMar · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The "NiTraSarc" trial evaluates the efficacy and feasibility (as determined by the safety and tolerability) of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas
Timeline
- Start
- 2018-06-08
- Primary completion
- 2022-02-12
- Completion
- 2022-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Trabectedin | Small molecule | 1.5 mg/m2 | Intravenous |